Chubb in the News

Life Sciences
 

Insuring Global Clinical Trials, Pharmaceutical Executive, January 9, 2009
As clinical trial sponsors look to foreign countries to conduct clinical trials, they need to consider international regulations and laws and their potential consequences.

A Panoramic View: What Life Sciences Firms Can Learn from Insurance Carriers that Take a Holistic Approach to Underwriting, The Journal of BioLaw & Business, Vol. 10, Number 2, 2007
To really understand the risk profile of a specific biotech, underwriters must take a long-term view of the company and the exposures associated with different stages of product development.

An Ounce of Prevention, BioExecutive International, November 2006
Developing relationships with first responders can help life sciences companies keep manageable incidents from becoming costly disasters.

Critical Coverage, European Pharmaceutical Contractor, Autumn 2006
The storage of refrigerated stock is a key exposure faced by most contract manufacturing and research organizations. This article discusses how to assess and manage this critical risk.

Global Perspectives on the Life Sciences Industry , The Journal of BioLaw & Business, Vol. 9, Number 3, 2006
This article highlights the latest trends and developments in litigation, regulation, risk management and insurance that are affecting biotech companies worldwide; in addition, it includes observations about the insurance needs of biotechnology companies in the United States, Canada, Europe, Australia, Asia and Latin America.

Contingency Planning: Preparation is the Key to Recovering from Disasters, The Journal of BioLaw & Business, Vol. 9, Number 2, 2006
Businesses in any industry can reel from the repercussions of electrical outages, fires, computer hackers or the ravages of Mother Nature. When such disruptions occur, these companies may be forced to halt operations for days, weeks or even months. These businesses can and do recover, but in some sectors, like biotechnology, business interruptions that result from such events are potentially catastrophic. This article provides an overview of practical items that should be considered by all life sciences companies as part of contingency planning.

Risky Business?, European Pharmaceutical Contractor, Autumn 2005
This article by Chris Tait discusses the idea that "risk" is not always as ominous or random as the word suggests. More often than not, the risks pharmaceutical companies face can be considered, planned for and, in many cases, managed so that business can flourish.

Insuring International Clinical Trials: Navigating the Quirks and Avoiding the Quagmires, The Journal of BioLaw, Volume 8, Number 3, 2005
The recent enactment of the European Union (EU) directive on human clinical research illustrates the ever-increasing complexity of multi-site clinical research. This article discusses the importance of insurance protection against liability in international clinical trials.

Will Your Firm Be a Victim of Medical Technology Error & Omissions Litigation, The Journal of BioLaw & Business, Volume 8, Number 2, 2005
This article highlights best risk management practices for companies, with a focus on errors and omissions liability and insurance protection.

Legal Landscape Heats Up for Life Science Companies, The Journal of BioLaw & Business, Volume 7, Number 1, 2004
This article discusses how biotechnology and life science companies--from the largest and the wealthiest to the smallest--can reduce the risk of product liability litigation and the prudent risk management steps that can be taken to improve their defense posture and reduce their exposure to large jury verdicts.

Navigating the International Insurance Market, The Journal of BioLaw & Business, Vol. 6, Number 3, 2003
This article identifies some of the risks facing biotechnology companies conducting business or research in foreign countries. It provides information that can help these firms navigate the intricate web of international insurance issues.

Heading Off a Clinical Trial Liability Lawsuit, Applied Clinical Trials, April 2003
This article by Jill Wadlund offers positive steps that sponsors can take toward limiting their exposure to liability lawsuits, even in the face of increasing litigation. Observing best practice procedures may offer more than the opportunity for a better insurance program. Sponsor companies may experience greater success in enrolling subjects when they have a reputation for superior clinical trial safety efforts. In addition, investors are likely to place greater importance on the way companies manage these exposures.

Improving Your Risk Profile May Result in Insurance Savings, AdvaMed Business Solutions, February 2003
This article by Frank Goudsmit and Jill Wadlund discusses the relationship between a medical device company and its insurer. When medical device companies select an insurance carrier that specializes in providing coverage to medical technology companies the benefits are many. Working together, the company and insurer can reduce losses, lower insurance costs and ultimately help the company succeed in the marketplace.

Surviving A Catastrophe: Are You Prepared?, The Journal of BioLaw & Business, Volume 6, Number 1, 2003
This article by Philip Fiscus discusses specific protective measures that biotechnology companies should consider to survive a catastrophe with a minimum amount of damage. Planning ahead and taking the time to develop comprehensive plans would reduce the likelihood and impact of a disaster; enable companies to respond quickly and effectively to an emergency and ensure the safety of employees. Establishing contingencies help companies to stay in business during a disaster and resume normal business operations as quickly as possible.

PDFs require the free Adobe Acrobat Reader. Get it here.